Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: A monocentric cohort study in China

BMC Gastroenterology

Huaxin Ding²  Qiubo Zhang¹  Danping Wang³  Lina Wu¹  Hongna Lu¹  Xie Zhang¹  Zhigang Huang¹ 

[1] Department of Gastroenterology, Lihuili Hospital of Ningbo Medical Center, 57# Xingning Road, Ningbo 315000, China;Ningbo Diagnostic Pathology Center, 2# Guanghua Road, Ningbo 315000, China;Ningbo University, 818# Fenghua Road, Jiangbei District, Ningbo 315000, China

关键词: Pepsinogen;    Serum trefoil factors;    Diagnosis;    Gastric cancer;   

Others  :  855629
DOI  :  10.1186/1471-230X-14-74

 received in 2013-11-22, accepted in 2014-03-24,  发布年份 2014

【 摘 要 】

Background

The search for better non-invasive biomarkers for gastric cancer remains ongoing. We investigated the predictive power of serum trefoil factor (TFF) levels as biomarkers for gastric cancer in comparison with the pepsinogen (PG) test.

Methods

Patients with gastric cancer, chronic atrophic gastritis (CAG) or chronic non-atrophic gastritis (CNAG), and healthy people were recruited. Serum concentrations of TFFs, PG I, and PG II, as well as the presence of antibodies against Helicobacter pylori, were measured by enzyme-linked immunosorbent assays (ELISA). Receiver operating characteristics (ROC) were used to compare the predictive powers of the selected factors.

Results

The serum concentrations of TFF1, TFF2, and TFF3 in the control groups were significantly lower than those in the gastric cancer group with the exception of TFF2 which was elevated in CAG. The area under the ROC curve for TFF3 was greater than that for the PG I/II ratio (0.81 vs 0.78). TFF3 also had a significantly higher predictive power for distinguishing gastric cancer than the PG test (odds ratio: 10.33 vs 2.57). Moreover, combining the serum TFF3 and PG tests for gastric cancer had better predictive power than either alone.

Conclusions

Serum TFF3 may be a better predictor of gastric cancer than the PG test, while the combined testing of serum PG and TFF3 could further improve the efficacy of gastric cancer screening.

【 授权许可】

   
2014 Huang et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
• [2]Oshima A, Hirata N, Ubukata T, Umeda K, Fujimoto L: Evaluation of a mass screening program for stomach cancer with a case–control study design. Int J Cancer 1986, 38:829-833.
• [3]Fukao A, Tsubono Y, Tsuji I, Hlsamichi S, Suqahara N, Takano A: The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case–control study. Int J Cancer 1995, 60:45-48.
• [4]Abe Y, Mitsushima T, Nagatani K, Lkuma H, Minamihara Y: Epidemiological evaluation of the protective eff ect for dying of stomach cancer by screening programme for stomach cancer with applying a method of case–control study—a study of an effi cient screening programme for stomach cancer. Nippon Shokakibyo Gakkai Zasshi 1995, 92:836-845.
• [5]Miki K, Fujishiro M, Kodashima S, Yahaqi N: Long-term results of gastric cancer screening using the serum pepsinogen test method among an asymptomatic middle-aged Japanese population. Dig Endosc 2009, 21:78-81.
• [6]Hamashima C, Shibuya D, Yamazaki H, Lnoue K, Fukao A, Saito H, Sobue T: The Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008, 38:259-267.
• [7]Miki K: Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - “ABC method”. Proc Jpn Acad Ser B Phys Biol Sci 2011, 87:405-414.
• [8]Thim L, May FE: Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci 2005, 62:2956-2973.
• [9]Taupin D, Podolsky DK: Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003, 4:721-732.
• [10]Bossenmeyer-Pourié C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C, Rio MC: The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 2002, 157:761-770.
• [11]Chan MW, Chan VY, Leung WK, Chan KK, To KF, Sung JJ, Chan FK: Anti-sense trefoil factor family-3 (intestinal trefoil factor) inhibits cell growth and induces chemosensitivity to adriamycin in human gastric cancer cells. Life Sci 2005, 76:2581-2592.
• [12]Yio X, Diamond M, Zhang JY, Weintein H, Wang LH, Werther L, Itzkowitz S: Trefoil factor family-1 mutations enhance gastric cancer cell invasion through distinct signaling pathways. Gastroenterology 2006, 130:1696-1706.
• [13]Emami S, Rodrigues S, Rodrigue CM, Le Floch N, Rivat C, Attoub S, Bruyneel E, Gespach C: Trefoil factor family (TFF) peptides and cancer progression. Peptides 2004, 25:885-898.
• [14]Yio X, Zhang JY, Babyatsky M, Chen A, Lin J, Fan QX, Werther JL, Itzkowitz S: Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells. Clin Exp Metastasis 2005, 22:157-165.
• [15]Chan VY, Chan MW, Leung WK, Leung PS, Sung JJ, Chan FK: Intestinal trefoil factor promotes invasion in non-tumorigenic Rat-2 fibroblast cell. Regul Pept 2005, 127:87-94.
• [16]Graness A, Chwieralski CE, Reinhold D, Thim L, Hoffmann W: Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion. J Biol Chem 2002, 277:18440-18446.
• [17]Wright NA, Poulsom R, Stamp G, Van Noorden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C: Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Gastroenterology 1993, 104:12-20.
• [18]Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murque B, Debeaumount M, Sands BE, Mahida YR: Identification of human intestinal trefoil factor, Goblet cell-specific expression of a peptide targeted for apical secretion. J Biol Chem 1993, 268:6694-6702.
• [19]Poulsom R, Hanby AM, Lalani EN, Hauser F, Hoffmann W, Stamp GW: Intestinal trefoil factor (TFF 3) and pS2 (TFF 1), but not spasmolytic polypeptide (TFF 2) mRNAs are co-expressed in normal, hyperplastic, and neoplastic human breast epithelium. J Pathol 1997, 183:30-38.
• [20]Devine DA, High AS, Owen PJ, Poulsom R, Bonass WA: Trefoil factor expression in normal and diseased human salivary glands. Hum Pathol 2000, 31:509-515.
• [21]Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W: Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J 2000, 14:1126-1131.
• [22]Dos Santos SE, Ulrich M, Doring G, Botaenhart K, Gott P: Trefoil factor family domain peptides in the human respiratory tract. J Pathol 2000, 190:133-142.
• [23]Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J, Lai M: Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010, 9:545-555.
• [24]Qu Y, Yang Y, Ma D, Xiao W: Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer. Oncol Rep 2012, 27:1277-1283.
• [25]Aikou S, Ohmoto Y, Gunji T, Matsuhashi N, Ohtsu H, Miura H, Kubota K, Yamagata Y, Seto Y, Nakajima A, Goldenring JR, Kaminishi M, Nomura S: Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology 2011, 141:837-845. e1-7
• [26]Bignotti E, Ravaggi A, Tassi RA, Calza S, Rossi E, Falchetti M, Romani C, Bandiera E, Odicino FE, Pecorelli S, Santin AD: Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. Br J Cancer 2008, 99:768-773.
• [27]Vestergaard EM, Borre M, Poulsen SS, Nexø E, Tørring N: Plasma levels of trefoil factors are increased in patients with advanced prostate cancer. Clin Cancer Res 2006, 12:807-812.
• [28]Dinis-Ribeiro M, Yamaki G, Miki K, Nexø E, Tørring N: Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. J Med Screen 2004, 11:141-147.
• [29]Shiga T, Nomoto K, Nisizawa M: A study of accuracy of serum pepsinogen method in mass screening and a mass screening using serum pepsinogen. J Gastroenterol Mass Surv 2000, 38:490-495.
• [30]Yoshihara M, Sumii K, Haruma K, Kiyohira K, Hattori N, Tanaka S, Kajiyama G, Shigenobu T: The usefulness of gastric mass screening using serum pepsinogen levels compared with photofl uorography. Hiroshima J Med Sci 1997, 46:81-86.
• [31]Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA: Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999, 44:693-697.
• [32]Mizuno S, Kobayashi M, Tomita S, Onoyama M, Habu Y, Inokuchi H, Watanabe Y: Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastric Cancer 2009, 12:158-163.
• [33]Iijima K, Abe Y, Kikuchi R, Koike T, Ohara S, Sipponen P, Shimosegawa T: Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. World J Gastroenterol 2009, 15:853-859.
• [34]Yanaoka K, Oka M, Yoshimura N, Mukoubayashi C, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Yamamichi N, Fujishiro M, Takeshita T, Mohara O, Ichinose M: Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and Helicobacter pylori antibody levels. Int J Cancer 2008, 123:917-926.
• [35]Kaise M, Miwa J, Tashiro J, Ohmoto Y, Morimoto S, Kato M, Urashima M, Ikegami M, Tajiri H: The combination of serum trefoil factor 3 and pepsinogen testing is a valid non-endoscopic biomarker for predicting the presence of gastric cancer: a new marker for gastric cancer risk. J Gastroenterol 2011, 46:736-745.
• [36]Camorlinga-Ponce M, Flores-Luna L, Lazcano-Ponce E, Herrero R, Bernal-Sahagún F, Abdo-Francis JM, Aguirre-García J, Muñoz N, Torres J: Age and severity of mucosal lesions influence the performance of serologic markers in Helicobacter pylori-associated gastroduodenal pathologies. Cancer Epidemiol Biomarkers Prev 2008, 17:2498-2504.
• [37]Muller W, Borchard F: pS2 protein in gastric carcinoma and normal gastric mucosa: association with clincopathological parameters and patient survival. J Pathol 1993, 171:263-269.
• [38]Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, Wendling C, Tomasetto C, Chambon P, Rio MC: Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996, 274:259-262.
• [39]Im S, Yoo C, Jung JH, Choi HJ, Yoo J, Kang CS: Reduced Expression of TFF1 and Increased Expression of TFF3 in Gastric Cancer: Correlation with Clinicopathological Parameters and Prognosis. Int J Med Sci 2013, 10:133-140.
• [40]Kirikoshi H, Katoh M: Expression of TFF1, TFF2 and TFF3 in gastric cancer. Int J Oncol 2002, 21:655-659.
• [41]Meng JR, Tang HZ, Zhou KZ, Shen WH, Guo HY: TFF3 and surviving expressions associate with a lower survival rate in gastric cancer. Clin Exp Med 2012, 13:297-303.